This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have already started or will start one of the following treatments for T2D or CKD: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP-1 RA), Steroidal mineralocorticoid receptor antagonists (sMRA), Finerenone a non-steroidal mineralocorticoid receptor antagonist (nsMRA), Other nsMRA (only in Japan). The main purpose of the study is to collect and describe characteristics of patients in each treatment group before and after finerenone became available. To do this, the researchers will collect data on: • Patient characteristics (e.g., age sex) of the participants • Clinical characteristics (e.g., history of CKD and T2D, heart and liver health, other health problems) of the participants • Treatments for T2D and CKD • Other medications used Data will be grouped by type of treatment that is initiated (e.g., SGLT2i, a GLP-1 RA, a sMRA, finerenone, or other nsMRA). Two time periods will be compared. Period I is the time until finerenone became available in the respective country, starting from 2012 (2014 for Japan). Period II will begin when finerenone becomes available in the respective country and will end at the end of the study (planned in September 2024). Researchers will also collect data on treatment patterns and changes in baseline characteristics in both time periods. Existing health care data will be collected from various sources in six countries (e.g., Denmark, Japan, the Netherlands, Spain, UK, and US). Besides this data collection, no further tests or examinations are planned in the study. The patients will receive their treatment as prescribed by their doctors during routine practice. Each patient will be in the study from first use of one of the listed drug classes until: • End of study • The data are somehow no longer available • The patient leaves or has to leave the study